Newsroom

Sorted by: Latest

-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust...
-

Riassunto: Blackfuel rende di dominio pubblico le sue operazioni annunciando la sigla di contratti per oltre 250 milioni di dollari finalizzati alla realizzazione di un network a livello globale per la generazione di token IA

PARIGI--(BUSINESS WIRE)--Blackfuel oggi ha reso di dominio pubblico le sue operazioni annunciando la sigla di contratti pluriennali per oltre 250 milioni di dollari finalizzati a raggiungere un ambizioso obiettivo: creare un network a livello globale per la generazione di token IA (“AI Token Grid”). Pioniera dell’AI Token Grid, Blackfuel sta sviluppando una rete di cluster di acceleratori per specifiche architetture, interconnessi attraverso un livello software e commerciale comune, progettata...
-

Blackfuel stellt sich erstmals öffentlich vor – mit einem vertraglich gesicherten Umsatz von über 250 Millionen USD zur Entwicklung eines globalen KI-Token-Rasters

PARIS--(BUSINESS WIRE)--Blackfuel hat sich heute mit einem durch mehrjährige Kundenverträge vertraglich zugesicherten Umsatz von über 250 Millionen USD erstmals öffentlich vorgestellt und seine Ambitionen kundgetan, ein globales KI-Token-Raster zu entwickeln. Blackfuel baut mit seinem wegweisenden KI-Token-Raster ein Netzwerk architekturspezifischer Beschleuniger-Cluster, die durch eine gemeinsame Software- und kommerzielle Schicht verbunden sind und dedizierte Rechenkapazität in messbare, rese...
-

Resumen: Blackfuel sale a la luz con más de 250 millones de dólares en ingresos por contrato para construir una red global de tokens de IA

PARÍS--(BUSINESS WIRE)--Blackfuel salió a la luz hoy con más de 250 millones de dólares en ingresos por contrato en acuerdos plurianuales con clientes y reveló su ambición de construir una red global de tokens de IA. Como pionero de la red de tokens de IA, Blackfuel está construyendo una red de clústeres de aceleradores de arquitectura específica conectados a través de un software y una capa comercial comunes, diseñados para convertir cómputo dedicado en resultados de IA medibles y asignables....
-

Samenvatting: Blackfuel komt uit de schaduw met meer dan 250 miljoen dollar aan contractueel vastgelegde inkomsten voor de bouw van een wereldwijd AI-token-netwerk

PARIJS--(BUSINESS WIRE)--Blackfuel is vandaag uit de anonimiteit getreden met meer dan 250 miljoen dollar aan opbrengsten uit meerjarige klantovereenkomsten, en heeft daarbij zijn ambitie bekendgemaakt om een wereldwijd AI-token-netwerk op te zetten. Als pionier van het AI-tokennetwerk bouwt Blackfuel aan een netwerk van architectuurspecifieke accelerator-clusters. Deze zijn verbonden via een gemeenschappelijke software- en commerciële laag, die is ontworpen om specifieke rekenkracht om te zett...
-

Massachusetts Financial Services Company UK Regulatory Announcement: Form 8.3 PROLOGIS, INC.

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3 easyJet Plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3 Intertek Group Plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...
-

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab). Un...